title: Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma.
abstract: Factor V activation is a critical step preceding prothrombinase formation. This study determined the contributions of factor Xa and thrombin, which activate purified factor V with similar catalytic efficiency, to plasma factor V activation during coagulation. Prothrombin activation began without a lag phase after a suspension of coagulant phospholipids, CaCl2, and factor Xa was added to factor X-depleted plasma. Hirudin, a potent thrombin inhibitor, abrogated prothrombin activation initiated with 0.5 and 1.0 nM factor Xa, but not with 5 nM factor Xa. In contrast, hirudin did not abrogate prothrombin activation in plasmas pre-incubated with 0.5, 1.0 or 5 nM alpha-thrombin for 10 s followed by the coagulant suspension containing 0.5 nM factor Xa. Thus, thrombin activates plasma factor V more efficiently than factor Xa. At concentrations which doubled the clotting time of contact-activated normal plasma, heparin and three low Mr heparins also abrogated prothrombin activation initiated with 0.5 nM factor Xa, but not with 5 nM factor Xa. If factor V in the factor X-depleted plasma was activated (by pre-incubation with 10 nM alpha-thrombin for 60 s) before adding 0.5, 1.0, or 5 nM factor Xa, neither hirudin nor the heparins altered the rates of prothrombin activation. Thus, none of the five anticoagulants inactivates prothrombinase. When 5 or 10 pM relipidated r-human tissue factor and CaCl2 were added to normal plasma, heparin and the three low Mr heparins delayed the onset of prothrombin activation until the concentration of factor Xa generated exceeded 1 nM, and they subsequently inhibited prothrombin activation to the same extent.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Canadian Red Cross Society, Blood Services, Hamilton Centre, Ontario.
authors.forename: F A
authors.initials: FA
authors.lastname: Ofosu
authors.forename: J C
authors.initials: JC
authors.lastname: Lormeau
authors.forename: S
authors.initials: S
authors.lastname: Craven
authors.forename: L
authors.initials: L
authors.lastname: Dewar
authors.forename: N
authors.initials: N
authors.lastname: Anvari
mesh_terms: D005165:Factor V / Q000187:drug effects*; D015951:Factor Xa / Q000494:pharmacology*; D006493:Heparin / Q000494:pharmacology*; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology*; D006629:Hirudins / Q000494:pharmacology; D006801:Humans; D011516:Prothrombin / Q000187:drug effects; D011994:Recombinant Proteins / Q000494:pharmacology; D013917:Thrombin / Q000494:pharmacology*; D013925:Thromboplastin / Q000037:antagonists & inhibitors / Q000187:drug effects* / Q000494:pharmacology
chemical_list: D006495:Heparin, Low-Molecular-Weight; D006629:Hirudins; D011994:Recombinant Proteins; D005165:Factor V; D011516:Prothrombin; D006493:Heparin; D013925:Thromboplastin; D013917:Thrombin; D015951:Factor Xa